Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract.

Abstract

Nineteen patients with recurrent or metastatic transitional cell carcinoma of the urinary tract were treated with a 3-weekly combination of methotrexate 200 mg/m2 as a 24-h infusion with folinic acid rescue and cis-platin 100 mg/m2. An objective response rate of 68% was obtained, with 4 patients (21%) achieving complete remission. Pulmonary disease and lymph node metastases were particularly sensitive to this therapy. The median duration of response was 21 weeks with a median survival of 54 weeks in the responding patients. This regimen warrants further investigation in the treatment of invasive bladder carcinoma.

• Authors: J Carmichael, M A Cornbleet, R H MacDougall, S G Allan, W Duncan, G D Chisholm, J F Smyth
• Journal: British journal of urology (Br J Urol) Vol. 57 Issue 3 Pg. 299-302 (Jun 1985) ISSN: 0007-1331 [Print] England
• PMID: 3873976 (Publication Type: Journal Article)

Chemical References

• Cisplatin
• Leucovorin
• Methotrexate

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Transitional Cell (drug therapy)
• Cisplatin (administration & dosage, adverse effects)
• Humans
• Leucovorin (administration & dosage)
• Methotrexate (administration & dosage, adverse effects)
• Middle Aged
• Neoplasm Metastasis
• Urologic Neoplasms (drug therapy)